ETON - Eton Pharmaceuticals XGen launch low blood pressure drug Rezipres

Eton Pharmaceuticals (NASDAQ:ETON) and XGen Pharmaceuticals DJB commercially launched Rezipres (ephedrine hydrochloride) injection. Rezipres (4.7 mg/mL) is a ready-to-use formulation of injectable ephedrine hydrochloride approved to treat clinically important hypotension (low blood pressure) occurring in the setting of anesthesia. XGen DJB’s hospital sales force will be responsible for commercializing the product, and Eton will continue to retain ownership of the product’s new drug application on file with the FDA.

For further details see:

Eton Pharmaceuticals, XGen launch low blood pressure drug Rezipres